Coya Therapeutics Book Value Per Share Growth & History (COYA)
Coya Therapeutics's book value per share was $2.06 for fiscal 2025.
View full Coya Therapeutics company overviewCoya Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.06 | -$0.31 | −13.23% |
| 2024 | 2024-12-31 | $2.37 | -$0.10 | −4.24% |
| 2023 | 2023-12-31 | $2.47 | $9.11 | — |
| 2022 | 2022-12-31 | -$6.64 | -$4.65 | — |
| 2021 | 2021-12-31 | -$1.99 | — | — |
Coya Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.84 | $0.15 | +8.99% |
| Q1 2026 | 2026-03-31 | $2.09 | $0.09 | +4.63% |
| Q4 2025 | 2025-12-31 | $2.06 | -$0.31 | −13.23% |
| Q3 2025 | 2025-09-30 | $1.63 | -$0.47 | −22.51% |
| Q2 2025 | 2025-06-30 | $1.69 | -$0.62 | −26.92% |
| Q1 2025 | 2025-03-31 | $2.00 | -$0.22 | −9.99% |
| Q4 2024 | 2024-12-31 | $2.37 | -$0.10 | −4.24% |
| Q3 2024 | 2024-09-30 | $2.10 | $1.09 | +107.36% |
| Q2 2024 | 2024-06-30 | $2.32 | $0.98 | +73.93% |
| Q1 2024 | 2024-03-31 | $2.22 | $0.59 | +36.52% |
| Q4 2023 | 2023-12-31 | $2.47 | $9.11 | — |
| Q3 2023 | 2023-09-30 | $1.01 | — | — |
| Q2 2023 | 2023-06-30 | $1.33 | — | — |
| Q1 2023 | 2023-03-31 | $1.62 | — | — |
| Q4 2022 | 2022-12-31 | -$6.64 | -$4.65 | — |
| Q4 2021 | 2021-12-31 | -$1.99 | — | — |
Coya Therapeutics book value per share trends
Between the periods ended 2021-12-31 and 2025-12-31, Coya Therapeutics's book value per share increased from -$1.99 to $2.06, a change of $4.04. The latest reported quarter, Q2 2026, shows $1.84.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Coya Therapeutics source filings ↗